Patents by Inventor David M. Young

David M. Young has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 4287184
    Abstract: Healing of a wound is accelerated by administering a new form of nerve growth factor having a molecular weight of about 116,000 and which is stable in dilute aqueous solutions. The nerve growth factor is obtained from mouse submandibular gland or mouse saliva. An extract of mouse submandibular gland or mouse saliva is subjected to ion-exchange chromatography to recover a component of the gland or saliva rich in the nerve growth factor and containing proteinaceous material which does not degrade the nerve growth factor. The pure nerve growth factor is obtained by subjecting the component rich in nerve growth factor to at least one additional chromatography step, usually two to four, to recover pure nerve growth factor having a molecular weight of about 116,000. The nerve growth factor is applied directly to the wound.
    Type: Grant
    Filed: September 19, 1979
    Date of Patent: September 1, 1981
    Assignee: The Massachusetts General Hospital
    Inventor: David M. Young
  • Patent number: 4249526
    Abstract: An inhalation device for powdered medicaments in which the opening of the container in which the medicament is initially contained is achieved simply and reliably in situ in the device, the device being provided with means (24) for locating the container in a position to be opened and with appropriate opening means (20, 21) for the container, said opening means being normally in a non-opening position but movable successively into and out of a container opening position by movement in one direction of a cam surface (7, 8, 30, 31) acting thereon, the cam surface being provided with a step or steps (9, 10) to prevent reverse movement of the cam surface after opening of the container has been achieved. The cam surface (7, 8) is preferably provided on one housing member (1) and the opening means (20, 21) on a second housing member (2) so that attachment of the housing members (1, 2) simultaneously opens the container.
    Type: Grant
    Filed: April 12, 1979
    Date of Patent: February 10, 1981
    Assignee: Fisons Limited
    Inventors: Desmond A. Dean, David M. Young
  • Patent number: 4230691
    Abstract: An antibody is prepared from a stable new form of nerve growth factor having a molecular weight of about 116,000. The pure nerve growth factor is obtained from an extract of mouse submandibular gland or mouse saliva which is subjected to ion-exchange chromatography to recover a component of the gland or saliva rich in the nerve growth factor and containing proteinaceous material which does not degrade the nerve growth factor. The component rich in nerve growth factor is subjected to at least one additional chromatography step, usually two to four, to obtain pure nerve growth factor. The pure nerve growth factor then is injected into the blood system of an animal to form the antibody which is recovered from the animal's blood serum.
    Type: Grant
    Filed: May 23, 1978
    Date of Patent: October 28, 1980
    Assignee: The Massachusetts General Hospital
    Inventor: David M. Young
  • Patent number: 4185095
    Abstract: A new form of nerve growth factor having a molecular weight of about 116,000 and which is stable in dilute aqueous solutions is obtained from mouse submandibular gland or mouse saliva. An extract of mouse submandibular gland or mouse saliva is subjected to ion-exchange chromatography to recover a component of the gland or saliva rich in the nerve growth factor and containing proteinaceous material which does not degrade the nerve growth factor. The pure nerve growth factor is obtained by subjecting the component rich in nerve growth factor to at least one additional chromatography step, usually two to four, to recover pure nerve growth factor having a molecular weight of about 116,000.
    Type: Grant
    Filed: November 23, 1977
    Date of Patent: January 22, 1980
    Assignee: The Massachusetts General Hospital
    Inventor: David M. Young
  • Patent number: 4104126
    Abstract: Substrates such as haptens and antigens, and those for receptor proteins and native circulating binding proteins are assayed by determining bacteriolysis products occasioned by bacteriophage infection of host cells, in a modification of the "chemically modified bacteriophage assay." Thus, a substrate such as an antigen is conjugated with bacteriophage and the conjugate competes with antigen in the specimen under assay for a limited number of binding sites on antibody. Phage conjugate surviving antibody inactivation is quantified by determining intracellular constituents of host bacteria subsequently infected by the bacteriophage remaining viable, which latter can be related to the levels of antigen originally present in the specimen. A preferred embodiment involves colorimetric assay for beta galactosidase freed by phage lysis of E. coli. Generally, the method is of sensitivity comparable to that of radioimmunoassay, but is attended by substantial advantages not common to the latter technique.
    Type: Grant
    Filed: November 19, 1976
    Date of Patent: August 1, 1978
    Assignee: Nichols Institute of Endocrinology, Inc.
    Inventor: David M. Young